Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Cree

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Neurologist|July 13, 2006
Emerging monoclonal antibody therapies for multiple sclerosisBruce Cree
Current Neurology and Neuroscience Reports|August 21, 2008
Neuromyelitis optica: diagnosis, pathogenesis, and treatmentBruce Cree
JAMA Neurology|September 10, 2014
Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial?Bruce Cree
Neurology|January 22, 2010
Does race matter for multiple sclerosis?Bruce Cree, Emmanuelle Waubant
Current Opinion in Neurology|March 26, 2025
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating successBruce Cree, Hans-Peter Hartung
Neurology|September 30, 2009
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosisElena Salvatore, Vincenzo Brescia Morra, Giuseppe Orefice, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2005
Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosisTil Menge, Patrice H Lalive, Hans-Christian von Büdingen, et al.
Archives of Neurology|October 13, 2010
Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis opticaSudhakar Reddy Kalluri, Zsolt Illes, Rajneesh Srivastava, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
NPJ Digital Medicine|October 21, 2020
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT studyYijun Zhao, Tong Wang, Riley Bove, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Neurologist|July 13, 2006
Emerging monoclonal antibody therapies for multiple sclerosisBruce Cree
Current Neurology and Neuroscience Reports|August 21, 2008
Neuromyelitis optica: diagnosis, pathogenesis, and treatmentBruce Cree
JAMA Neurology|September 10, 2014
Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial?Bruce Cree
Neurology|January 22, 2010
Does race matter for multiple sclerosis?Bruce Cree, Emmanuelle Waubant
Current Opinion in Neurology|March 26, 2025
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating successBruce Cree, Hans-Peter Hartung
Neurology|September 30, 2009
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosisElena Salvatore, Vincenzo Brescia Morra, Giuseppe Orefice, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2005
Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosisTil Menge, Patrice H Lalive, Hans-Christian von Büdingen, et al.
Archives of Neurology|October 13, 2010
Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis opticaSudhakar Reddy Kalluri, Zsolt Illes, Rajneesh Srivastava, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
NPJ Digital Medicine|October 21, 2020
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT studyYijun Zhao, Tong Wang, Riley Bove, et al.
Pageof 2